Patent · US Active

CD70 combination therapy

US11712468B2 · kind B2 · utility

2Cited by

28References

36Claims

0Family size

Assignees

argenx BV · BE
UNIVERSITAT BERN · CH

Inventors

Johannes Joseph Wilhelmus De Haard · Vlaardingen, NL
Samson FUNG · Wondelgem, BE
Nicolas Leupin · Zürich, CH
Adrian OCHSENBEIN · Wondelgem, BE
Carsten RIETHER · Bern, CH
Luc Van Rompaey · Mechelen, BE

Key dates

Filing date	Dec 18, 2019
Grant date	Aug 1, 2023
Priority date	—
Expiry date	Sep 12, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/545
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.